Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Theravance Biopharma (TBPH) over the last 11 years, with Q3 2023 value amounting to $24000.0.

  • Theravance Biopharma's Current Deferred Revenue changed 0.0% to $24000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $24000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $24000.0 for FY2022, which is 7551.02% down from last year.
  • As of Q3 2023, Theravance Biopharma's Current Deferred Revenue stood at $24000.0, which was down 0.0% from $24000.0 recorded in Q2 2023.
  • Theravance Biopharma's Current Deferred Revenue's 5-year high stood at $43.3 million during Q2 2019, with a 5-year trough of $24000.0 in Q2 2022.
  • Its 5-year average for Current Deferred Revenue is $12.9 million, with a median of $5.7 million in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 9957.82% in 2022, then changed by 0.0% in 2023.
  • Theravance Biopharma's Current Deferred Revenue (Quarter) stood at $31.6 million in 2019, then tumbled by 63.51% to $11.5 million in 2020, then crashed by 99.15% to $98000.0 in 2021, then tumbled by 75.51% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
  • Its Current Deferred Revenue was $24000.0 in Q3 2023, compared to $24000.0 in Q2 2023 and $24000.0 in Q1 2023.